Artificial Intelligence is set to enhance the field of pathology without replacing doctors or drastically altering the industry’s economics in the near future, said Metropolis Healthcare Chairperson Ameera Shah.
Metropolis has been adopting a cautious approach to AI, concentrating on selective and high-impact applications instead of widespread implementation, she said during earnings call.
Current AI use at Metropolis includes targeted areas such as test interpretation, quality monitoring, and customer engagement, while future applications aim to optimize workflows and enhance decision support. Additionally, Metropolis emphasises genomics and advanced specialty testing, viewing this segment as a crucial growth driver for both B2C and B2B markets in the coming years
India’s diagnostics sector is shifting from a phase of aggressive capital inflows, discount-driven growth, and weak unit economics to a phase of consolidation focused on scale, sustainable growth, and profitability.
In this changing scenario, Metropolis is well positioned due to its strong brand recognition, scientific leadership, and extensive network across India. The company is actively seeking quality, affordable acquisitions to expand its market presence, she said.
Metropolis crossed a milestone by securing its first patent for a tuberculosis monitoring system, underscoring its commitment to innovation. Looking ahead, while seasonal trends are less predictable post-COVID, the company is optimistic about strong momentum entering the typically robust fourth quarter.
According to her, Metropolis Healthcare is confident of achieving 12–13% organic growth in FY26, supported by strong channel traction, improved productivity, and an optimized test mix.
The company also expects gradual margin expansion through scale benefits, operational efficiencies, material productivity, and careful cost management.
As the diagnostics sector consolidates and technology transforms laboratory operations, Metropolis aims to establish itself as a science-led diagnostics platform focused on accuracy, consistency, and clinical trust.
CFO Sameer Patel said that estimated capex for the year ₹55-60 crore. This is largely towards strengthening and expanding pan-India network, upgrading IT systems and processes, scaling up high-end equipment to support advanced and super specialty test capabilities.
Speaking about liquidity position and cash strength, he said the company remains net debt-free with a current cash reserves of ₹127 crore. We will continue to accumulate cash to fund and support our future growth initiatives.